Zobrazeno 1 - 10
of 62
pro vyhledávání: '"razumab"'
Autor:
Vivek Basavprabhu Wani, Ankita Agarwal, Arvind L Tenagi, Bhagyajyothi Khanagavi, Shivanand Channabasu Bubanale, Nagbhushan Chougule, Chethana Warad
Publikováno v:
Indian Journal of Health Sciences and Biomedical Research KLEU, Vol 16, Iss 2, Pp 225-230 (2023)
BACKGROUND: Razumab is a biosimilar of ranibizumab and its intravitreal injection in various retinal diseases has been reported with good results. However, the incidence of inflammation in the anterior chamber and vitreous after the intravitreal inje
Externí odkaz:
https://doaj.org/article/a916635618b144b4affff7a1b4a3b1c5
Autor:
Shashikant Sharma, Vishali Gupta, Aniruddha Maiti, Sribhargava Natesh, Sandeep Saxena, Vivek Dave, Vimal Parmar, Raju Sampangi, Hemanth Murthy, Sandhya Dharwadkar, Naresh Kumar Yadav, Shrinivas Joshi, Rahul Mayor, Dhanashree Ratra, Soumyava Basu, Neha Goel, Alok Chaturvedi, Ronak Patel, Vinu Jose
Publikováno v:
International Journal of Retina and Vitreous, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract Background Razumab™ (world’s first biosimilar ranibizumab) is approved for several macular disorders including wet age-related macular degeneration (AMD). We evaluated the safety and efficacy of biosimilar ranibizumab in wet AMD. Methods
Externí odkaz:
https://doaj.org/article/bb8509736af64a8799ac8af46ca70d15
Autor:
Jay U Sheth, Michael W Stewart, Manoj Khatri, Shashank R Gupta, Shobhit Chawla, Anand Rajendran, Raja Narayanan
Publikováno v:
Indian Journal of Ophthalmology, Vol 69, Iss 2, Pp 352-356 (2021)
Purpose: The aim of this study was to present the outcomes of the 2018 and 2020 Vitreo-retinal Society of India (VRSI) biosimilars of anti-vascular endothelial growth factor (VEGF) (VIBE) surveys. Methods: An online survey of members of VRSI was cond
Externí odkaz:
https://doaj.org/article/0a3f1c9fff19430a9f61a1db19d38bcd
Publikováno v:
Indian Journal of Ophthalmology, Vol 69, Iss 2, Pp 347-351 (2021)
Purpose: The aim of this study was to evaluate the efficacy and safety of Razumab (the biosimilar Ranibizumab by Intas Pharmaceuticals Ltd.) for the treatment of chorioretinal vascular diseases such as diabetic macular edema (DME), choroidal neovascu
Externí odkaz:
https://doaj.org/article/9a6ebbeaf3e241009935cc9a6f25405f
Publikováno v:
Indian Journal of Ophthalmology, Vol 69, Iss 6, Pp 1469-1474 (2021)
Purpose: The aim of this study was to evaluate the safety, efficacy, and morphological response of intravitreal ranibizumab biosimilar (Razumab) in neovascular age-related macular degeneration (n-AMD) up to 12 weeks. Methods: Retrospective analysis o
Externí odkaz:
https://doaj.org/article/a4b57cb443c542b7bd81595610feeed2
Publikováno v:
Ophthalmology and Therapy, Vol 9, Iss 3, Pp 625-639 (2020)
Abstract Purpose The REal life assessmENt of safety And effeCTiveness of Razumab 2 (RE-ENACT 2) study evaluated the long-term effectiveness of biosimilar ranibizumab. We present the subgroup analysis of patients with retinal vein occlusion (RVO). Met
Externí odkaz:
https://doaj.org/article/b1682f44c5e64863837e5a1858953581
Autor:
Sriram Gopal, Supraja Kasturirangan, Nivean Madhivanan, Henderson Henry, Pratheeba Devi Nivean, Sangeetha Shekharan
Publikováno v:
TNOA Journal of Ophthalmic Science and Research, Vol 58, Iss 3, Pp 154-158 (2020)
Context: This study was done to evaluate the effectiveness and safety of biosimilar Razumab for the treatment of diabetic macular edema (DME), neovascular age related macular degeneration (ARMD), and cystoid macular edema (CME) due to retinal vein oc
Externí odkaz:
https://doaj.org/article/39bb6e47744b486f846effbe5033a1da
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Clinical Ophthalmology, Vol Volume 12, Pp 2137-2143 (2018)
Ashish Sharma,1 Prahalad Reddy,1 Baruch D Kuppermann,2 Bandello Francesco,3 Anat Lowenstein41Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India; 2Department of Ophthalmology, Gavin Herbert Eye Institute, Unive
Externí odkaz:
https://doaj.org/article/676b3cc895384c879856be8c32b38788
Publikováno v:
Kerala Journal of Ophthalmology, Vol 28, Iss 3, Pp 180-185 (2016)
Aim: The aim of this study was to evaluate the safety and efficacy of biosimilar intravitreal ranibizumab (Razumab) for the treatment of chorioretinal vascular diseases such as diabetic macular edema (DME), neovascular age-related macular degeneratio
Externí odkaz:
https://doaj.org/article/fcedc97a51f344a69c7ffec1c96c0728